Compounding Chemotherapy Market Trends, Size, Segments, Sales and Analysis by Forecast to 2030
Compounding Chemotherapy Market Overview
The market is estimated to grow at
a CAGR ( Compound Annual Growth Rate ) of 6.04 % over the current forecast
period ( 2022-2030 ).
Compounding is the science of combining and developing drugs that
are unique to the needs of the patients. These medications are made depending
on the recommendation of the doctor in which the individual constituents are
mixed in accordance with the prescribed dose.
Many technical advances and cutting-edge strategies have allowed
pharmacies to respond to the needs of clinicians and boost the growth of the
global Compounding
Chemotherapy Market. Furthermore, the increasing opioid scarcity
s is expected to increase demand globally for compounding chemotherapy.
Compounding Chemotherapy Market
Segmentation
Compounding chemotherapy industry has been
considered for dose, compounding type, delivery method, sterility, technology,
compounder type, and application.
Compounding chemotherapy market, dose-wise, caters
to chemotherapeutic as well as non-chemotherapeutics. Chemotherapeutics
obtained the leading position in 2019 and is anticipated to witness significant
growth in the following years, backed by the soaring burden of cancer, rising
spending on medicine and surge in health benefits.
The various compounding types studied in the MRFR
report are currently unavailable pharmaceutical manufacturing (CUPM), pharmaceutical
dosage alteration (PDA) and pharmaceutical ingredient alteration (PIA). The PDA
segment should perform relatively better than its counterparts in the given
period.
The compounding chemotherapy market, in terms of
delivery method, can be narrowed down into volumetric automated compounding
device (volume-based) and gravimetric automated compounding device
(weight-based). In 2019, the lead was secured by the gravimetric automated
compounding device (weight-based) segment.
Depending on sterility, the global market has been
split based on sterile and non-sterile. The sterile segment, with the biggest
share of 56.0%, attained the top spot in 2019. Chemotherapy that is based on
sterile substances is used as injections and infusions.
Major technologies analyzed in the market study are
robotic arms as well as without robotic arms. The with robotic arm is the top
segment and is anticipated to procure a growth rate of 6.46% in the years
ahead.
Compounder types listed in the MRFR report are
Equashield Pro, Pharmoduct, Integra, Medimix, and others. Since 2019,
pharmoduct has remained the market leader and is set to attain a CAGR of 7.84%.
Applications of compounding chemotherapy are
respiratory/lung cancer, blood cancer, breast cancer, gastrointestinal cancer,
prostate cancer, and others.
Compounding Chemotherapy Market Regional Analysis
Compounding chemotherapy industry has been
regionally divided into Europe, the Americas, MEA or Middle East & Africa
as well as APAC or Asia Pacific.
The American market can be considered for two
regions, namely North America and Latin America, while the North America market
is further segmented into Canada as well as the US. The American market has
secured the lead and is soaring at a tremendous pace thanks to the rising cases
of cancer, escalating healthcare costs, and the urgent need for advanced
chemotherapy. The broad focus on creating modern healthcare practices and
improving cancer-based treatment benefits the American industry. The expanding
elderly population that is prone to different types of cancer also drive the
market value. The Population Reference Bureau reveals that the geriatric
populace in the United States is anticipated to touch 24% of the global
population by the year 2060. These numbers ensure that the demand for
compounding chemotherapy remains steady in the coming years.
During the analysis period, the European market is
likely to take the second lead, in terms of revenue, on account of the surge in
government-backed research activities to find a breakthrough for cancer, which
is rising at an alarming pace in the region. The high healthcare costs,
presence of reputed companies as well as well-developed healthcare facilities
also add to the market size in the region.
The APAC market for compounding chemotherapy is
split into India, China, South Korea, Japan, and Australia. Asia Pacific has
strong growth potential since the government across various countries are
lending support to the healthcare industry for vigorous research and
development activities, especially in China and India. Moreover, the rapid
growth in cancer cases, massive demand for effective therapies, burgeoning
aging population and mounting public awareness regarding cancer and the latest
treatment options also enhance the market size in the region
KeyPlayers.
Compounding Chemotherapy Market Players are,
- Pfizer
Inc.
- Baxter
- Grifols
SA
- Comecer
S.P.A.
- Added
Pharma
- Equashield
- Arxium
- Dedalus
Group
- B.
Braun Melsungen AG
- Omnicell
- Icon
group
- The
Metrix Company
- Loccioni
- Sterline
S.R.L.
- Millers
Pharmacy
At Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private
Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment